Hyperproteinaemia after Velagliflozin (Senvelgo) in cats

The FDA has received 97 reports of hyperproteinaemia in cats after Velagliflozin. That is 2.0% of all reports for this medicine, compared with 0.4% across reports for all cat medicines, so it is reported unusually often with this medicine.

97Reports

47%Marked serious

5.2%Recovered

26%Died or euthanised

21 daysTypical onset

How soon it started

Same day

4 5.2%

1–2 days

6 7.8%

3–7 days

15 19%

1–4 weeks

21 27%

Over a month

31 40%

How the animals did

Recovered

5 5.2%

Still unwell when reported

11 11%

Died

7 7.2%

Euthanised

18 19%

Not known

56 58%

Problems reported at the same time

57 59%

56 58%

46 47%

46 47%

43 44%

41 42%

39 40%

34 35%

Age of the animals

Under 1 year

1–3 years

4–7 years

8–11 years

12+ years

About this medicine

Velagliflozin treats diabetes in cats (oral, an SGLT2 inhibitor).

Products with this ingredient include Senvelgo. The FDA hides brand names in its public data, so these reports cover every product with the same active ingredients.

Questions owners ask

Can Velagliflozin cause hyperproteinaemia in cats?: 97 reports link the two, but a report alone does not prove the medicine was the cause: other illnesses, other medicines or coincidence can be involved. Your vet can judge it for your animal.
How soon after a dose was it reported?: In half of the reports with dates, it started within 21 days of the first dose.
What should I do?: Don't give another dose until you've spoken to your vet, and keep the packaging so you can tell them the product and dose. Your vet can also report it to the FDA (or you can, through the manufacturer or FDA form 1932a).

Hyperproteinaemia with similar medicines

Hyperproteinaemia after Bexagliflozin (Bexacat) 51 reports · 1.3% of its reports

All reported side effects of Velagliflozin in cats · Medicines most reported with hyperproteinaemia